Peer-reviewed veterinary case report
Cilostazol improves nerve and blood flow in dogs with spinal nerve
By Sekiguchi, Miho et al.·Published in Spine·2008·Department of Orthopaedic Surgery, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model.
- Species:
- dog
Plain-English summary
A group of dogs with nerve compression in their lower back were treated with a medication called cilostazol to see if it could improve nerve function and blood flow. The results showed that dogs receiving a medium dose of cilostazol had better nerve conduction compared to those who didn't receive the treatment. In another part of the study, dogs treated with cilostazol for chronic compression also showed significant improvements in both nerve function and blood flow. This suggests that cilostazol could help dogs with issues related to nerve compression in their spine.
People also search for: dog nerve compression treatment · cilostazol for dogs · improving dog blood flow · dog spinal issues medication
Abstract
STUDY DESIGN: Analyses of improvements in nerve conduction velocity (NCV) and blood flow after administering cilostazol in a dog model of experimental acute and chronic cauda equina compression. OBJECTIVE: To determine whether cilostazol improves NCV and blood flow, and cilostazol inhibits blood clots in capillaries of nerve roots after cauda equina compression. SUMMARY AND BACKGROUND DATA: Reduction in blood flow is an important factor in neurogenic intermittent claudication for lumbar spinal stenosis. Prostaglandin E1 (PGE1) and calcitonin have been reported to improve blood flow and neurogenic intermittent claudication in clinical and experimental studies. Cilostazol affects vasodilator and antiplatelet activity, and protects endothelial cells in blood vessels. METHODS: Experimental groups in the acute compression study (n = 40) were divided into 4 treatment groups. Low-dose (3 microg/kg/min), medium-dose (10 microg/kg/min), or high-dose (30 microg/kg/min) cilostazol or a control vehicle were administered intravenously after cauda equina compression. NCV and blood flow were measured during the observation period (n = 20 measurements for each). Another 12 animals were used to evaluate chronic compression. Cilostazol was administered for 6 days orally 1 day after compression treatment group (n = 6); the nontreatment group (n = 6) did not receive any drug. NCV was measured immediately after and 7 days after compression. Blood flow was measured 7 days after compression. RESULTS: In the acute compression study, NCV in the medium-dose group was significantly higher than that in the other groups during the compression period (P < 0.05). During the recovery period, there was no significant difference in NCV among groups. In the chronic compression study, NCV and blood flow in the cilostazol group were significantly higher than those in the control group (P < 0.05). CONCLUSION: Cilostazol improved NCV and blood flow to the cauda equina in this dog model. Cilostazol might be a potential agent to improve symptoms due to compression of cauda equina and/or cauda equina dysfunction.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19011541/